Executive Director, Science and Regulatory
Sara Wang has over 30 years of working experience in the healthcare industry including Regulatory Affairs, Research and Development, Clinical Operations and Medical Affairs. Sara joined RDPAC in 2018 as the Head of Science & Regulatory Affairs.
Sara led RDPAC member companies to actively participate in the regulatory advocacy activities, support the implementation and transformation of ICH guidelines in China, and advance China’s participation in the simultaneous R&D and registration of global innovative drugs. She has led a number of research projects in RDPAC, which have conducted in-depth research and analysis on relevant topics in drug review and approval and clinical research system, sharing international experience and put forward suggestions.
Before joined RDPAC, Sara worked in Novartis, GSK and Baxter for many years, taking different roles in Regulatory Affairs and R&D. She started her carrier in the Institute of Material Medica, Chinese Academy of Medical Sciences, and worked there for 5 years in research and development.